Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $98.42 Consensus Target Price from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $98.4167.

Several equities research analysts recently commented on ARWR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Morgan Stanley raised their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Sanford C. Bernstein lifted their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Leerink Partners boosted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Adeoye Olukotun sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $3,533,000. California State Teachers Retirement System boosted its position in Arrowhead Pharmaceuticals by 7,797.6% during the second quarter. California State Teachers Retirement System now owns 11,397,217 shares of the biotechnology company’s stock worth $928,987,000 after purchasing an additional 11,252,904 shares during the period. Washington Trust Advisors Inc. grew its holdings in Arrowhead Pharmaceuticals by 3.6% during the second quarter. Washington Trust Advisors Inc. now owns 26,185 shares of the biotechnology company’s stock valued at $2,134,000 after purchasing an additional 911 shares during the last quarter. Compass Financial Management LLC acquired a new position in Arrowhead Pharmaceuticals during the second quarter valued at approximately $179,000. Finally, AlphaGrep UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $375,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $86.34 on Thursday. The stock has a market cap of $12.16 billion, a price-to-earnings ratio of -38.37 and a beta of 1.28. Arrowhead Pharmaceuticals has a 1 year low of $27.10 and a 1 year high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock has a fifty day moving average price of $84.11 and a 200 day moving average price of $74.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. During the same quarter last year, the firm earned ($1.26) EPS. The business’s revenue for the quarter was up 171.0% compared to the same quarter last year. Analysts forecast that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.